Skip to main content

Table 2 Treatment outcome of patients treated with azacitidine or intensive chemotherapy

From: Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

  Azacitidine (N=26) Intensive chemotherapy (N=90) P-value
All (N=90) Excl. allo-SCT (N = 76) Aza vs all IC Aza vs IC excl. allo-SCT
Overall survival      
 1-year 57% 56% 50% 0.931 0.801
 2-year 35% 35% 31% 0.921 0.501
Response, overall 11 (42%) 68 (76%) 54 (71%) <0.001 0.005
 CR 9 (35%) 63 (70%) 49 (65%)
 PR 2 (8%) 5 (6%) 5 (7%)
 No CR or PR 15 (58%) 22 (24%) 22 (29%)
Early death      
 within 4 weeks 1 (4%) 4 (4%) 4 (4%) 0.881 0.791
 within 8 weeks 2 (8%) 11 (12%) 11 (12%) 0.511 0.401
Relapse/death after response      
 within 1 year 4 (36%) 39 (57%) 34 (63%) 0.211 0.181
 within 2 years 5 (45%) 42 (62%) 37 (69%) 0.301 0.141
Days in hospital, median (range)      
 month 1–3 0.5 (0–30) 56 (2–85) 54 (2–85) <0.001 0.029
 month 4–6 0 (0–8) 0 (0–81) 0 (0–81) 0.036 0.006
RBC transfusions, median per month (range)      
 month 1–3 2.7 (0–10) 7 (0–32) 7 (0–32) <0.001 <0.001
 month 4–6 0 (0–13) 1 (0–8) 0 (0–8) 0.97 0.65
PLT transfusions, median per month (range)      
 month 1–3 0.3 (0–7) 5 (0–19) 5 (0–19) <0.001 <0.001
 month 4–6 0 (0–1) 0 (0–8) 0 (0–8) 0.016 0.047
  1. 1Log rank test. Patients with promyelocytic leukaemia (N = 14) were excluded from this analysis. Abbreviations: excl. allo-SCT, excluding patients undergoing allogeneic hematopoietic stem cell transplantation; IC, intensive chemotherapy; Aza, azacitidine; vs, versus; CI, confidence interval; CR, complete remission; PR, partial remission; RBC, red blood cell; PLT, platelet. Results are reported as N (%) unless otherwise indicated.